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Dexmedetomidine is a highly selective 𝛼2 agonist used as a sedative agent. It also provides anxiolysis and sympatholysis without
significant respiratory compromise or delirium. We conducted a systematic review to examine whether sedation of patients in
the intensive care unit (ICU) with dexmedetomidine was associated with a lower incidence of delirium as compared to other
nondexmedetomidine sedation strategies. A search of PUBMED, EMBASE, and the Cochrane Database of Systematic Reviews
yielded only three trials from 1966 through April 2015 that met our predefined inclusion criteria and assessed dexmedetomidine
and outcomes of delirium as their primary endpoint. The studies varied in regard to population, comparator sedation regimen,
delirium outcome measure, and dexmedetomidine dosing. All trials are limited by design issues that limit our ability definitively
to conclude that dexmedetomidine prevents delirium. Evidence does suggest that dexmedetomidine may allow for avoidance of
deep sedation and use of benzodiazepines, factors both observed to increase the risk for developing delirium. Our assessment of
currently published literature highlights the need for ongoing research to better delineate the role of dexmedetomidine for delirium
prevention.

1. Introduction
Delirium is an acute fluctuation in mental status that manifests with inattention, disorganized thinking, and/or an
altered level of consciousness [1]. It occurs often in critically
ill patients, with as many as 20% to 50% of nonventilated
patients and 60% to 80% of mechanically ventilated patients
reported to develop delirium [1]. Intensive care unit (ICU)
delirium is associated with a number of detrimental outcomes
including longer ICU and hospital length of stay, increased
costs, and long-term cognitive impairment [2–5]. Additionally, patients who develop ICU delirium experience increased
mortality risk, with rates exceeding three times those of
matched, nondelirious ICU patients within 6 months of critical illness [2]. A number of modifiable and nonmodifiable

risk factors may predispose patients to ICU delirium [6].
Medications used for sedation, agitation, and anxiety are
widely considered the most influential in terms of ICU delirium risk. Current strategies for delirium prevention focus
on maximizing nonpharmacologic interventions, effectively
treating pain, allowing for early mobility of patients and implementation of sedation protocols targeting light sedation,
often including daily sedation interruption and the avoidance
of benzodiazepines [6–8].
Benzodiazepines are historically the medication class of
choice for provision of sedation and treatment of agitation in
the ICU; however, they repeatedly have been identified as a
risk factor for development of delirium in adult ICU patients
[8–10]. As the presence of delirium has been associated with
negative outcomes, delirium prevention may be the most
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effective way to reduce its associated morbidity and mortality
[11]. The identification of a nondeliriogenic sedation strategy is therefore of paramount importance for critical care
medicine. Roberts and colleagues emphasize this point and
conclude that a shift in practice is needed in considering the
pharmacology of sedatives and the duration of sedation [12].
Currently, no medications are approved by the Food
and Drug Administration (FDA) for the prevention of ICU
delirium. Guidelines for the treatment of pain, agitation, and
delirium in critically ill patients supported by the Society of
Critical Care Medicine also do not provide recommendations
on pharmacologic delirium prevention [8]. However, many
studies have suggested that the use of dexmedetomidine for
sedation is associated with lower incidence of delirium and
improved outcomes associated with delirium when compared
to benzodiazepine or opioid-based sedation strategies in
mechanically ventilated patients; dexmedetomidine also has
been associated with lower rates of agitation in delirious
patients compared to conventional treatments [13–19].
We present a systematic review of randomized controlled
trials (RCTs) reporting on the efficacy of dexmedetomidine
with respect to a primary outcome of delirium prevention in
any ICU population. We surmise that adult patients receiving
sedation with dexmedetomidine as compared to nondexmedetomidine sedation strategies will exhibit a lower incidence
of delirium.

2. Literature Identification
A search was performed of MEDLINE, EMBASE, and the
Cochrane Database of Systematic Reviews from 1966 through
April 2015. Search terms included “dexmedetomidine,” “delirium (MeSH term),” “ICU psychosis,” “encephalopathy,”
“alpha-2 agonist,” and “agitation.” The search was limited to
the English language and human subjects. Study type was limited to randomized controlled trials (RCTs), controlled trials,
or comparative studies. Reference lists of articles retrieved
were searched for the identification of any possibly relevant
publications. The search was last performed on 20 April 2015
independently by two authors (S. Nelson and A. J. Muzyk).
Studies were eligible for inclusion if they were RCTs of
adult subjects (18 years or older) hospitalized in any ICU and
were designed to assess the primary outcome of dexmedetomidine’s efficacy on delirium prevention in a prospective
manner. To be included in the systematic review studies were
required to employ validated delirium detection or diagnostic
tools such as the Confusion Assessment Method for the ICU
(CAM-ICU), the Intensive Care Delirium Screening Checklist (ICDSC), or the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR) definition in conjunction
with the Delirium Rating Scale (DRS) [20–22]. Nonrandomized trials and those that report solely on delirium measures
as secondary outcomes were excluded but were retained for
discussion and context.
Two authors (A. J. Muzyk and J. P. Gagliardi) read
abstracts independently and assessed appropriateness for
inclusion in the systematic review. Disagreements were resolved by discussion with a third author (M. Bucklin) until
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consensus was reached. For each study, data necessary for
critical evaluation were extracted (see Table 1). This includes
study design, inclusion and exclusion criteria, patient population and demographic data, intervention (including drug and
dosing utilized), method of delirium detection, and results.
Articles were appraised for validity using the Jadad [23] score
(which ranges from 0: very poor to 5: rigorous).
Seventy-one studies were identified through initial literature search, with 42 abstracts meeting inclusion requirements; 17 articles from MEDLINE, 21 articles from EMBASE,
and four articles were found in the Cochrane Database of
Systematic Reviews. Of these, 38 were excluded because
they were case reports, nonrandomized open-label trials, or
review articles, or they did not report on delirium as the primary outcome. No additional articles were identified based
on reference review. This left 4 RCTs of dexmedetomidine for
the prevention of delirium. One study was excluded as it was
a subgroup analysis of data reported in another of the eligible
trials.
The three remaining trials are summarized below [13–
15]. As they differ significantly in regard to baseline patient
characteristics, ICU type, primary outcome, the use of an
active comparator, and dosing of dexmedetomidine, a metaanalysis was not appropriate and not undertaken.

3. Literature Evaluation
The first RCT was conducted by Pandharipande and colleagues [13]. They included adults hospitalized at two tertiary
care hospitals in medical and surgical ICUs who received
mechanical ventilation for at least 24 hours. Exclusion criteria
targeted potential subjects in whom delirium assessment
would be difficult (non-English speaking or severe hearing difficulties) or confounded (neurological disease, severe
dementia, and Child-Pugh class B or C) and in whom benzodiazepine therapy may be necessary (active seizure, alcohol
abuse, and benzodiazepine dependency). The exclusion criteria also targeted those at risk of cardiotoxicity of dexmedetomidine (active myocardial infarction and second- or thirddegree heart block) and those who were pregnant or lactating.
Potential subjects were also excluded if family or physician
refused consent or if they were moribund, with planned withdrawal of life support. Subjects were randomized to a doubleblind infusion of either dexmedetomidine (dose ranges from
0.15 to 1.5 mcg/kg/h) or lorazepam (dose ranges from 1 mg/h
to 10 mg/h). Presence of delirium was assessed for 12 days
or until hospital discharge using the CAM-ICU, and coma
was assessed utilizing the Richmond Agitation Sedation Scale
(RASS), with coma defined as a RASS score of −4 or −5.
Primary outcomes of this study were a composite end point of
delirium-free and coma-free days and the percentage of days
spent within 1 RASS point of the predefined sedation goal.
One hundred and three subjects were included in the
primary analysis with no significant differences in baseline
characteristics between treatment groups, though a higher
proportion of subjects randomized to dexmedetomidine had
received fentanyl prior to randomization. The majority of
subjects were hospitalized for sepsis, acute respiratory distress syndrome, or for a pulmonary complication. Compared
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Table 1: Description of study methods and validity criteria.

ICU type
Subjects
Number
Age (median, IQR)
Male gender (%)
Intervention (median, IQR)

Primary outcome
Randomization
Concealment
Blinding
Jadad Score

Pandharipande et al. (2007)
[13]

Shehabi et al. (2009) [14]

Maldonado et al. (2009) [15]

Medical/surgical

Cardiothoracic

Cardiothoracic

103
Dexmedetomidine: 60
(49–65)
Lorazepam: 59 (45–67)
51.5

299
Dexmedetomidine: 71.5
(66–76)
Morphine: 71 (65–75)
75.3
Dexmedetomidine:
0.48 mcg/kg/h (0.23–0.76)
Morphine: 49 mcg/kg/h
(20–81)
Delirium incidence within 5
days of surgery
Computer-generated blocks of
10
Known only to study
pharmacist
Solutions identical in color
(clear)
3

90
Dexmedetomidine: 55 (16)∗
Propofol: 58 (18)∗
Midazolam: 60 (16)∗
63.6
Dexmedetomidine:
0.35 mcg/kg/h∗∗
Propofol: 26.3 mcg/kg/h∗∗
Midazolam: 1.5 mg/h∗∗
Incidence of post-operative
delirium
Random drawing the evening
before surgery, blocked

Dexmedetomidine:
0.74 mcg/kg/h (0.39–1.04)
Lorazepam: 3 mg/h (2.2–6)
Composite of delirium-free
and coma-free days
Computer generated,
permuted blocks
Known only to study
pharmacist
Solutions identical in color
(clear)
4

Open-label
Unblinded
2

∗: mean (SD); ∗∗: mean.

to subjects randomized to lorazepam, those sedated with
dexmedetomidine experienced more days without coma or
delirium (7 days dexmedetomidine versus 3 days lorazepam,
𝑝 = 0.01) and spent more time within 1 point of their RASS
goal (67% dexmedetomidine versus 55% lorazepam, 𝑝 =
0.008). Additionally, significantly fewer subjects treated with
dexmedetomidine experienced any delirium or coma compared to those treated with lorazepam. There was no significant difference between treatment groups on secondary outcomes of delirium-free days, duration of delirium, or prevalence of delirium. There was also no difference observed in
terms of concomitant medications used for sedation or delirium, mechanical ventilator free days, ICU length of stay, 28day mortality, or 12-month mortality. Regarding safety, subjects randomized to dexmedetomidine had significantly more
sinus bradycardia (17% versus 4%, 𝑝 = 0.03); one subject in
each group had a heart rate less than 40 beats per minute. The
rate of self-extubation did not differ between groups.
Benefits of dexmedetomidine over lorazepam were demonstrated only in the composite endpoints. Individual endpoint analysis yielded a statistically significant benefit of
dexmedetomidine on rate of coma but no difference between
sedation strategies in terms of delirium prevalence (79%
dexmedetomidine versus 82% lorazepam, 𝑝 = 0.65) and delirium-free days (9 dexmedetomidine versus 7 lorazepam, 𝑝 =
0.09). Similarly, the use of antipsychotics, presumably for the
treatment of delirium, was not significantly different between
groups (46% dexmedetomidine versus 35% lorazepam, 𝑝 =
0.26), further suggesting that the extent of delirium was
not reduced with the use of dexmedetomidine. As noted
above, the study may have been biased in that more subjects

randomized to dexmedetomidine had received fentanyl prior
to assignment to a study protocol. It is possible that the
prior use of opioids (which may predispose subjects to delirium) contributed to the development of delirium in the
dexmedetomidine group. While these limitations are significant, it is important to consider the ability of dexmedetomidine to achieve the goal of light sedation, a concept which
is becoming increasingly important for the reduction of
delirium in all critically ill patients. Also, it is unclear how
often the CAM-ICU was implemented to screen for delirium.
As delirium is a waxing and waning state, more rigorous
CAM-ICU assessments may have identified more delirium,
affecting the outcome observed.
The second RCT conducted by Shehabi and colleagues
included adults aged 60 years or greater undergoing on-pump
cardiac surgery at one of two tertiary care hospitals [14].
Potential subjects were excluded if they reported an allergy
to any study medication, had baseline dementia, Parkinson’s disease, or a seizure disorder, were receiving other 𝛼2
agonists, or were on psychoactive medications, excluding
nighttime hypnotics. Additionally, subjects were required to
understand the English language, to have had a preoperative heart rate > 55 bpm and/or systolic blood pressure
>90 mmHg, to weigh ≤150 kg, and to have no significant renal
impairment (serum creatinine ≤1.6 mg/dL or creatinine clearance ≥50 mL/min). Subjects were randomized to a blinded
infusion of either dexmedetomidine (dose ranges from
0.1 mcg/kg/h to 0.7 mcg/kg/h) or morphine (10 mcg/kg/h to
70 mcg/kg/h) without the use of loading doses. Infusions
were titrated based on a sedation protocol to a goal Motor
Activity Assessment Scale (MAAS) of 2 to 4. Open-label
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propofol (bolus and/or infusion) was allowed in both groups
for hypertensive episodes and unplanned awakening or to
meet goal sedation levels. Additionally, open-label morphine
was administered as a 1 to 2 mg IV bolus dose given every 15
minutes to achieve adequate pain control in both groups. The
primary outcome of this study was the percentage of subjects
who developed delirium as measured using the CAM-ICU
during the first five days following surgery.
Two hundred and ninety-nine subjects were included in
the primary analysis, with 152 patients randomized to dexmedetomidine and 147 to morphine. There were no significant
differences in baseline characteristic between the two groups.
The majority of subjects were males, over the age of 65 years,
hospitalized urgently for either a coronary bypass graft or a
valve replacement with/without a coronary graft requiring a
cross clamp time of approximately 60 minutes. Authors found
the incidence of delirium within five days of surgery not different between treatment groups (8.5% in dexmedetomidine
versus 15% in morphine, 𝑝 = 0.088). A secondary outcome
of delirium duration was shorter for subjects randomized to
dexmedetomidine versus morphine sedation (2 days versus 5
days, resp., 𝑝 = 0.0317). Subgroup analysis of those requiring
intraaortic balloon pump (IABP) for hemodynamic support
demonstrated a lower incidence of delirium in the dexmedetomidine group compared with the morphine group (15%
versus 36%, resp., 𝑝 = 0.001). Propofol was required in more
than 75% of all subjects regardless of treatment assignment
within 6 hours of cardiac surgery and was required in more
than one-third of all subjects thereafter. Morphine was used
with similar rates between study groups (approximately 12%
of all subjects 6 hours postoperatively). In regard to safety,
subjects randomized to dexmedetomidine experienced significantly more bradycardia (16.5% versus 6.1%, 𝑝 = 0.006)
and significantly less systolic hypotension (23% versus 38.1%,
𝑝 = 0.006).
Several limitations of this trial warrant discussion. As
with any study that aims to distinguish between sedation and
delirium, it may have been challenging to identify the optimal
timing for delirium assessment, and given the sedation of
subjects included in the study, delirium may have been underrecognized in both groups. Second, the majority of subjects
received propofol at some point during the postoperative
period, which clouds the purity of the comparison between
dexmedetomidine and morphine sedation strategies. Finally,
while investigators used a standard sedation protocol familiar
at the study sites, utilization of the MAAS is not commonplace in the United States, making it more difficult to accurately replicate or generalize the study methodology.
The final study meeting inclusion criteria was conducted
by Maldonado and colleagues [15]. They compared the incidence of postoperative delirium in an open-label, randomized, controlled fashion in patients undergoing cardiac surgery randomized to dexmedetomidine, propofol, or midazolam. Subjects were included if they were undergoing elective
valve operations and between the ages of 18 and 89. Exclusion criteria included preexisting dementia or schizophrenia, preoperative psychotropic medication use, active or
recent substance abuse/dependence, stroke within the last
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six months, advanced heart block, pregnancy, or anticipated need for deep hypothermic circulatory arrest. Subjects were randomized to an infusion of dexmedetomidine
(loading dose 0.4 mcg/kg and maintenance dose ranging
from 0.2 mcg/kg/h to 0.7 mcg/kg/h), propofol (dose ranges
from 25 mcg/kg/min to 50 mcg/kg/min), or midazolam (dose
ranges from 0.5 mg/h to 2 mg/h). Subjects received no other
agents to achieve or maintain goal sedation level (Ramsay
score of 3 for intubated patients and 2 for nonintubated
patients). Delirium was diagnosed based on DSM-IV-TR criteria and confirmed using the Delirium Rating Scale (DRS).
All subjects could receive fentanyl 25 to 50 mcg intravenously every hour as needed for pain within the first 24
hours postoperatively and ketorolac, hydrocodone, or oxycodone thereafter. If delirium was suspected, subjects could
receive haloperidol up to 5 mg intravenously every 6 hours as
needed in the first 24 hours, with haloperidol or lorazepam
as necessary thereafter. The primary outcome was the proportion of patients in each treatment group diagnosed with
postoperative delirium within the first 3 days following
cardiac surgery.
A total of 118 subjects met inclusion and exclusion criteria
and were randomized to one of three treatment arms. Authors
report a 24% dropout rate among subjects, mostly due to
protocol violation or clinical condition. Ninety subjects were
included in the perprotocol analysis with all 118 included in
the intention-to-treat analysis. Using both methods, subjects
randomized to dexmedetomidine exhibited significantly less
delirium than those randomized to propofol or midazolam
(10% dexmedetomidine, 44% propofol, and 44% midazolam
in intention-to-treat analysis, 𝑝 < 0.001). Those randomized
to dexmedetomidine also had fewer days of delirium (2
patient days dexmedetomidine, 45 patient days propofol, and
75 patient days midazolam, 𝑝 < 0.001), though the duration
of delirium was not significantly different between groups.
Adjunctive fentanyl use was significantly higher in subjects randomized to midazolam (320 mcg dexmedetomidine,
364 mcg propofol, and 1088 mcg midazolam). Importantly,
subjects randomized to propofol or midazolam were given
more as-needed lorazepam and haloperidol for delirium.
Though statistically nonsignificant, the percentage of subjects
administered lorazepam was different between groups (3%
dexmedetomidine, 23% propofol, and 20% midazolam, 𝑝 =
NS).
Strengths of this study include the use of protocolized
anesthesia and postoperative care in all groups, application
of a sedation protocol with a well validated sedation scoring
system, and the selection of a homogenous patient population. Limitations in this study are numerous, however, including the use of the DSM-IV-TR to diagnose ICU delirium
via a dedicated neuropsychiatrist and once daily delirium
assessments. Additionally, this study did not report any data
regarding the safety of the interventions evaluated. However
the most notable limitations in this study are its open-label
design, small sample size, and high dropout rate. Though
statistically nonsignificant, the differential use of as-needed
benzodiazepines may account for differences in delirium
between treatment groups and may have nothing to do with
the effect of dexmedetomidine itself.
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4. Discussion
Delirium is associated with a number of deleterious outcomes; therefore, the prevention of its development is important. Dexmedetomidine is a highly selective 𝛼2 agonist that
reduces norepinephrine release, producing sedation, anxiolysis, and sympatholysis. Numerous pathophysiologic mechanisms have been identified that may contribute to delirium
development, and dexmedetomidine may be helpful for many
of these [24, 25]. Excessive norepinephrine release, perhaps in
response to infection or inflammation in critically ill adults,
is part of a cascade of events hypothesized to lead to neuronal
damage and the development of delirium [26]. Reduction in
this neurotransmitter release through dexmedetomidine
administration may prevent or limit the risk for delirium
development. Excitatory amino acid (glutamate) toxicity,
gamma-aminobutyric acid (GABA) agonism, and acetylcholine deficiency have also been implicated in the development
of delirium [26, 27]. Dexmedetomidine therefore may also
be beneficial for delirium prevention through decreasing
glutamate release and its lack of GABA receptor modulation
or cholinergic receptor activity when compared to other commonly used sedatives [28, 29]. Additionally, dexmedetomidine may promote natural sleep patterns through stimulation
of 𝛼2 receptors leading to inhibition of noradrenergic neurons
in the locus ceruleus and disinhibition of GABA neurons in
the ventrolateral preoptic nucleus [30].
Despite these theoretical advantages, the evaluation of
dexmedetomidine for the prevention of delirium in clinical
trials has not clearly demonstrated benefit. The available body
of literature addressing this topic as a primary endpoint is
limited in quantity and quality. Other studies investigating
the benefit of dexmedetomidine have been reviewed in
four meta-analyses [31–34]. These meta-analyses are unique
from our review as they allowed for assessment of various
delirium outcomes, included delirium outcomes as primary
and secondary endpoints, were often focused on select patient
populations, and concurrently evaluated the effect of other
interventions on the outcome of delirium. Given the heterogeneity of the previously published analyses, outcomes
regarding the influence of dexmedetomidine on delirium in
these studies are varied. Zhang and colleagues published a
meta-analysis which demonstrated a lower rate of delirium
in postoperative patients receiving dexmedetomidine [31].
These findings differed from an earlier meta-analysis demonstrating no significant reduction in delirium with dexmedetomidine in a general population of critically ill adults in
the ICU [32]. Differences in methodology, populations, and
measurements make a comparison between meta-analyses
difficult, though one possibility is that dexmedetomidine may
be more effective in preventing delirium among surgical, but
not medical, patients [25, 33, 34].
In our review of the available literature examining prevention of delirium as a primary endpoint, utilization of dexmedetomidine did not routinely demonstrate benefit among
all ICU patient populations. This review is limited by the
small number of trials that met robust inclusion criteria, use
of varied comparator agents, and the inclusion of trials that
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inherently had their own limitations or bias, including openlabel studies.
Despite methodological limitations or the exclusivity
of critically ill populations examined, a common concept
that can be extracted from available literature is the benzodiazepine-sparing benefit of dexmedetomidine. Benzodiazepines are a known risk factor for the development of delirium and their use has been associated with oversedation and
prolonged mechanical ventilation. Utilization of dexmedetomidine rather than benzodiazepines may afford the ability
to maintain light sedation goals and an overall reduction in
the risk for the development of delirium, providing a role
for dexmedetomidine for the prevention of ICU delirium.
The 2013 clinical practice guidelines for the management of
pain, agitation, and delirium in adult ICU patients do not
clearly delineate when dexmedetomidine should be utilized
[8]. They do, however, suggest the use of nonbenzodiazepine
sedation regimens, including dexmedetomidine, that allow
for targeting light sedation. They also suggest that dexmedetomidine may be less deliriogenic as compared to other commonly used sedatives [8]. Additionally, dexmedetomidine
possesses a favorable pharmacokinetic profile for use in critically ill adults. It has a short onset of action allowing for
rapid sedation and ease of titration, an elimination half-life
of two hours, minimal drug-drug interaction potential, and
complete elimination from the body within 10 hours following infusion cessation [35]. Dexmedetomidine is rather well
tolerated with most adverse effects being cardiac in nature.
Bradycardia and hypotension are most common and usually
occur with bolus and loading dose administration [36].
As interest grows in the area of delirium prevention, the
role of dexmedetomidine should continue to be assessed and
defined. It is important to note that other pharmacologic
agents have been studied for delirium prevention, but demonstrating efficacy for delirium prevention has been elusive
[37]. As no clear pharmacologic prevention strategy has been
identified, use of dexmedetomidine to provide light sedation and avoid deliriogenic sedatives may be a reasonable
therapeutic option until further information is available.

5. Conclusion
Dexmedetomidine is a centrally acting 𝛼2 agonist that is FDAindicated for sedation in intubated, critically ill adults. It may
allow for better attainment of light sedation goals, a strategy
that is recommended in guidelines provided by the Society
of Critical Care Medicine, rather than conventional sedation agents including benzodiazepines and opioids. Through
attainment of light sedation and the sparing-effect of these
other sedatives, dexmedetomidine may indirectly decrease
the incidence of delirium. Its direct effect on the prevention
of delirium remains theoretical and unproven. Continued
attempts should be made to evaluate dexmedetomidine for
this indication through larger, randomized, placebo controlled trials in varied critically ill patient populations.
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